272 Efficacy & toxicity of gemcitabine and cisplatin in reccurrent platinum resistant ovarian cancer: single centre experience

• Published in: International journal of gynecological cancer Vol. 34; no. Suppl 1; p. A309
• Main Authors: Banerjee, Swarnabindu, Chowdhury, Hambir
• Format: Journal Article
• Language: English
• Published: Oxford BMJ Publishing Group Ltd 10.03.2024; BMJ Publishing Group LTD
• Subjects: Chemotherapy; Ovarian cancer; Patients; Poster and E-Posters; Toxicity
• ISSN: 1048-891X; 1525-1438
• DOI: 10.1136/ijgc-2024-ESGO.607

Introduction/BackgroundInspite of recent advancement in managing reccurrent epithelial ovarian cancer, like maintainace Bevacizumab, PARP inhibitors, majority requires chemotherapy. Once platinum resistance develops, treatment options become limited.We report the efficacy and safety of dose-dense cisplatin with gemcitabine chemotherapy for relapsed platinum-resistant ovarian cancer. Preclinical models in an ovarian cancer demonstrate synergistic activity with the combination of gemcitabine and cisplatin compared to either single agent alone. Platinum resistance is related to expression of excision repair proteins, one of which (ERCC-1) has been identified as playing a critical role in the synergy of gemcitabine and cisplatin. Our objective is to describe (D1/8) gemcitabine (1000 mg/m2) and cisplatin (30 mg/m2) for the treatment of recurrent platinum resistant ovarian cancer.MethodologyA retrospective review was performed of all patients with recurrent Platinum Resistant epithelial ovarian cancer, of last 5yrs who were treated with gemcitabine and cisplatin from August 2018 to August 2023 in gynaec-oncology department.400 patients met inclusion criteria.Data was collected from out patient and in patient records and analysed by descriptive and analytical statistics.ResultsThe median platinum-free treatment interval was 4 months Patients were treated with a median of 6 cycles of gemcitabine plus cisplatin. 120 patients had a complete clinical response with a median progression free survival (PFS) of 14months, 160 patients had a partial clinical response with median PFS 6 months. Stable disease was noted in 40 patients, with a median PFS of 24 months .80patients had progressive disease(PD). Commonest toxicity was haematological. Grade 1 anaemia(30%) .Dose limiting toxicity was thrombocytopenia, grade 3 in 5%. Neutropenic Sepsis was present in 3%.Non-hematologic toxicities were present in 23%.Commonest was grade 1 peripheral neuropathy and grade1 1 Acute Kidney Injury.ConclusionGemcitabine plus cisplatin (D1/D8) is a well tolerated and active regimen in patients with recurrent Platinum Resistant Ovarian Cancer.DisclosuresI do not have any conflict of interest.